

Goki Suda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7228241/publications.pdf>

Version: 2024-02-01

65
papers

1,238
citations

361045

20
h-index

433756

31
g-index

66
all docs

66
docs citations

66
times ranked

1704
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2016, 51, 733-740. | 2.3 | 103 |
| 2 | L-carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 910-922. | 2.0 | 67 |
| 3 | Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 2017, 38, 1073-1083. | 1.3 | 64 |
| 4 | Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids. <i>Frontiers in Immunology</i> , 2018, 9, 723. | 2.2 | 56 |
| 5 | Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 119-128. | 2.3 | 49 |
| 6 | Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2020, 4, 54-60. | 0.7 | 36 |
| 7 | Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977. | 1.8 | 35 |
| 8 | Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. <i>Journal of Gastroenterology</i> , 2021, 56, 67-77. | 2.3 | 34 |
| 9 | Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , 2017, 52, 1122-1129. | 2.3 | 32 |
| 10 | Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatology Research</i> , 2019, 49, 1294-1304. | 1.8 | 32 |
| 11 | Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <i>Hepatology Research</i> , 2017, 47, 1127-1136. | 1.8 | 31 |
| 12 | Hepatitis B virus X protein impairs interferon signaling via upregulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. <i>Journal of Medical Virology</i> , 2017, 89, 267-275. | 2.5 | 29 |
| 13 | Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. <i>PLoS ONE</i> , 2018, 13, e0209615. | 1.1 | 29 |
| 14 | Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180. | 2.3 | 29 |
| 15 | Analysis of the optimal psoas muscle mass index cutoff values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. <i>Hepatology Research</i> , 2020, 50, 715-725. | 1.8 | 28 |
| 16 | Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. <i>Hepatology Research</i> , 2016, 46, 1294-1303. | 1.8 | 27 |
| 17 | Treatment of hepatitis C in special populations. <i>Journal of Gastroenterology</i> , 2018, 53, 591-605. | 2.3 | 26 |
| 18 | IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. <i>Virology</i> , 2010, 407, 80-90. | 1.1 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | A pivotal role of KrÄ¼ppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1453-1461. | 1.5 | 22 |
| 20 | Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788. | 1.4 | 22 |
| 21 | Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. <i>Journal of Hepatology</i> , 2017, 67, 1106-1108. | 1.8 | 21 |
| 22 | Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 641-649. | 2.3 | 21 |
| 23 | Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glyco-biomarker for non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2020, 10, 321. | 1.6 | 21 |
| 24 | Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. <i>Carcinogenesis</i> , 2021, 42, 58-69. | 1.3 | 21 |
| 25 | Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2017, 89, 857-866. | 2.5 | 20 |
| 26 | High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. <i>Hepatology Research</i> , 2020, 50, 671-681. | 1.8 | 20 |
| 27 | Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989. | 1.8 | 20 |
| 28 | Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. <i>Journal of Gastroenterology</i> , 2022, 57, 120-132. | 2.3 | 20 |
| 29 | Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 78-86. | 2.3 | 19 |
| 30 | Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. <i>Hepatology Research</i> , 2019, 49, 1207-1217. | 1.8 | 19 |
| 31 | Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 320-327. | 0.7 | 18 |
| 32 | Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0261760. | 1.1 | 17 |
| 33 | Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. <i>Hepatology Research</i> , 2015, 45, 837-845. | 1.8 | 15 |
| 34 | Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <i>Hepatology Research</i> , 2018, 48, 529-538. | 1.8 | 15 |
| 35 | Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 880-888. | 0.7 | 13 |
| 36 | Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1152-1158. | 1.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Combination of neutrophil-to-lymphocyte ratio and early des β -carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 533-541. | 1.8 | 13 |
| 38 | A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. <i>Drugs in R and D</i> , 2017, 17, 381-388. | 1.1 | 12 |
| 39 | Quantifying Protein-Specific N-Glycome Profiles by Focused Protein and Immunoprecipitation Glycomics. <i>Journal of Proteome Research</i> , 2019, 18, 3133-3141. | 1.8 | 12 |
| 40 | Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of β 2,3-Linked Sialic Acid Residues. <i>Analytical Chemistry</i> , 2019, 91, 13343-13348. | 3.2 | 12 |
| 41 | Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19. <i>Hepatology Research</i> , 2020, 50, 1196-1200. | 1.8 | 11 |
| 42 | Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <i>Cancers</i> , 2021, 13, 3633. | 1.7 | 10 |
| 43 | Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. <i>Scientific Reports</i> , 2022, 12, 1449. | 1.6 | 9 |
| 44 | Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769454. | 0.8 | 8 |
| 45 | Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. <i>Hepatology Research</i> , 2019, 49, 1275-1285. | 1.8 | 8 |
| 46 | Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. <i>JCSM Rapid Communications</i> , 2020, 3, 103-114. | 0.6 | 8 |
| 47 | Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. <i>Scientific Reports</i> , 2021, 11, 9207. | 1.6 | 8 |
| 48 | Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. <i>Nutrients</i> , 2021, 13, 2415. | 1.7 | 8 |
| 49 | Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. <i>Journal of Viral Hepatitis</i> , 2021, 28, 755-763. | 1.0 | 6 |
| 50 | Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. <i>Scientific Reports</i> , 2021, 11, 16616. | 1.6 | 6 |
| 51 | Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232. | 1.7 | 6 |
| 52 | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , 2019, 58, 943-947. | 0.3 | 5 |
| 53 | Durable response without recurrence to Tolvaptan improves long-term survival. <i>Journal of Gastroenterology</i> , 2020, 55, 1150-1161. | 2.3 | 4 |
| 54 | Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , 2019, 58, 797-802. | 0.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-λ3 induction in chronic hepatitis B patients. <i>Hepatology Research</i> , 2022, 52, 586-596. | 1.8 | 4 |
| 56 | Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. <i>Hepatology Research</i> , 2022, , . | 1.8 | 4 |
| 57 | Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2076-2087. | 0.8 | 4 |
| 58 | Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728. | 1.1 | 3 |
| 59 | Genomic profiling of intestinal/mixed-type superficial non-ampullary duodenal epithelial tumors. <i>JGH Open</i> , 2021, 5, 1071-1077. | 0.7 | 2 |
| 60 | Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. <i>Hepatology Research</i> , 2018, 48, E146-E154. | 1.8 | 1 |
| 61 | Nutrition is often ignored in management of chronic liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1127-1128. | 1.4 | 1 |
| 62 | Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 389. | 1.3 | 1 |
| 63 | The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 508-521. | 1.8 | 1 |
| 64 | Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. <i>PLoS ONE</i> , 2022, 17, e0270786. | 1.1 | 1 |
| 65 | Evaluation of clinical utility of PIVKA-II using a chemiluminescent immunoassay. <i>Acta Hepatologica Japonica</i> , 2019, 60, 397-404. | 0.0 | 0 |